Julien Dubreucq, MD, PhD

Centre Référent de Réhabilitation psychosociale et de Remédiation cognitive (C3R), Centre Hospitalier Alpes Isère, Grenoble, France; Fondation FondaMental, Créteil, France; Institut Marc Jeannerod, UMR 5229, CNRS & Université Lyon, France 1; Réseau Handicap Psychique, Grenoble, France

JCP
Original Research

May 18, 2021

Female gender has been associated with better outcomes in schizophrenia spectrum disorders (SSDs). This study investigated gender differences in recovery-related outcomes and psychiatric rehabilitation needs in a multicenter sample...
Marine Dubreucq, Julien Plasse, Franck Gabayet, et al
JCP
Article

January 8, 2019

Extrapyramidal side effects have been identified as frequent side effects of antipsychotics in RCTs with highly selected subjects, but how common are they in nonselected samples? This national multicenter...
David Misdrahi, Arnaud Tessier, Antoine Daubigney, et al
JCP
Original Research

September 18, 2018

Cardiovascular diseases are the primary cause of mortality in individuals with schizophrenia, yet no study has yet explored the impact of metabolic syndrome on schizophrenia relapse. This study explored...
Ophelia Godin, Marion Leboyer, Frank Schürhoff, et al
JCP
Original Research

April 17, 2018

The relationship between insight and suicide in patients with schizophrenia is unclear. Read this article to learn the extent to which that relationship may be influenced by quality of...
Paul Roux, David Misdrahi, Delphine Capdevielle, et al
JCP
Original Research

September 28, 2016

Medication nonadherence among schizophrenia patients is common, but also possibly modifiable. Learn about how a patient self-report instrument—the MARS—can be used to identify nonadherence in these patients.
David Misdrahi, Arnaud Tessier, Joel Swendsen, et al

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe